 Lupus Erythematosus, Systemic
"Lupus Erythematosus, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Descriptor ID |
D008180
|
| MeSH Number(s) |
C17.300.480 C20.111.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lupus Erythematosus, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Lupus Erythematosus, Systemic".
This graph shows the total number of publications written about "Lupus Erythematosus, Systemic" by people in this website by year, and whether "Lupus Erythematosus, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1992 | 3 | 2 | 5 | | 1993 | 0 | 1 | 1 | | 1994 | 2 | 1 | 3 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 0 | 2 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 2 | 3 | | 2001 | 3 | 2 | 5 | | 2002 | 4 | 2 | 6 | | 2003 | 3 | 2 | 5 | | 2004 | 6 | 3 | 9 | | 2005 | 7 | 0 | 7 | | 2006 | 6 | 1 | 7 | | 2007 | 6 | 0 | 6 | | 2008 | 4 | 1 | 5 | | 2009 | 8 | 1 | 9 | | 2010 | 8 | 1 | 9 | | 2011 | 10 | 2 | 12 | | 2012 | 16 | 1 | 17 | | 2013 | 14 | 2 | 16 | | 2014 | 7 | 2 | 9 | | 2015 | 8 | 1 | 9 | | 2016 | 8 | 2 | 10 | | 2017 | 2 | 1 | 3 | | 2018 | 5 | 2 | 7 | | 2019 | 7 | 0 | 7 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Lupus Erythematosus, Systemic" by people in Profiles.
-
Klarquist J, Cantrell R, Lehn MA, Lampe K, Hennies CM, Hoebe K, Janssen EM. Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells. Immunohorizons. 2020 03 11; 4(3):140-152.
-
Theisen E, Lee DE, Pei S, Schauder DM, Chiu YE, Brandling-Bennett H, Curran ML, Klein-Gitelman M, Co DO, Arkin LM. Hypergammaglobulinemic purpura of Waldenström in children. Pediatr Dermatol. 2020 May; 37(3):467-475.
-
Godavarthy A, Kelly R, Jimah J, Beckford M, Caza T, Fernandez D, Huang N, Duarte M, Lewis J, Fadel HJ, Poeschla EM, Banki K, Perl A. Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation. JCI Insight. 2020 01 16; 5(1).
-
Sirobhushanam S, Parsa N, Reed TJ, Berthier CC, Sarkar MK, Hile GA, Tsoi LC, Banfield J, Dobry C, Horswill AR, Gudjonsson JE, Kahlenberg JM. Staphylococcus aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by IFN-Mediated Barrier Disruption. J Invest Dermatol. 2020 05; 140(5):1066-1074.e4.
-
Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147.
-
Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, Kamen DL, Gilkeson GS, Weisman MH, Karp DR, Gaffney PM, Harley JB, Wallace DJ, Norris JM, James JA. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019 09; 78(9):1235-1241.
-
Franks SE, Getahun A, Cambier JC. A Precision B Cell-Targeted Therapeutic Approach to Autoimmunity Caused by Phosphatidylinositol 3-Kinase Pathway Dysregulation. J Immunol. 2019 06 15; 202(12):3381-3393.
-
James JA, Chen H, Young KA, Bemis EA, Seifert J, Bourn RL, Deane KD, Demoruelle MK, Feser M, O'Dell JR, Weisman MH, Keating RM, Gaffney PM, Kelly JA, Langefeld CD, Harley JB, Robinson W, Hafler DA, O'Connor KC, Buckner J, Guthridge JM, Norris JM, Holers VM. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine. 2019 Apr; 42:76-85.
-
Young KA, Munroe ME, Guthridge JM, Kamen DL, Gilkensen GS, Harley JB, Weisman MH, Karp DR, Wallace DJ, James JA, Norris JM. Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE. Lupus. 2019 Apr; 28(5):597-606.
-
Boackle SA. Better Biomarkers for Lupus Disease Activity: Tools for Treating to Target. Arthritis Rheumatol. 2019 03; 71(3):329-330.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|